| Trial ID: | L4059 |
| Source ID: | NCT05591235
|
| Associated Drug: |
Metformin
|
| Title: |
Effect of Metformin, Dapagliflozin, Combination of Metformin and Pioglitazone in Patients With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type2diabetes|Insulin Resistance
|
| Interventions: |
DRUG: Metformin|DRUG: Dapagliflozin|DRUG: Fixed-dose combination of metformin and pioglitazone (500mg metformin plus 15mg pioglitazone)
|
| Outcome Measures: |
Primary: Insulin resistance, change from baseline insulin resistance at the fifth week, week 5 |
|
| Sponsor/Collaborators: |
Sponsor: Nanjing First Hospital, Nanjing Medical University
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
60
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2022-11
|
| Completion Date: |
2023-02
|
| Results First Posted: |
|
| Last Update Posted: |
2022-10-24
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT05591235
|
